Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q43299263

about

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets Targeted therapy for advanced renal cell carcinoma A comprehensive overview of targeted therapy in metastatic renal cell carcinoma Axitinib for the management of metastatic renal cell carcinoma Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Axitinib in Metastatic Renal Cell Carcinoma Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Magnetic resonance imaging and computed tomography characteristics of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients Targeted therapies in renal cell cancer: recent developments in imaging Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Sunitinib and other targeted therapies for renal cell carcinoma.Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Immunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Future directions in renal cell carcinoma: 2011 and beyond Targeting the tumor microenvironment: focus on angiogenesis.Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics VEGF spliced variants: possible role of anti-angiogenesis therapy.Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.Sunitinib re-challenge in advanced renal-cell carcinoma.

P2860

Q21183974-2895CE6F-5BE9-451F-B212-0DA60F27ADA0 Q24242946-C8D60322-0CD0-478A-B373-8759DBB1D2AC Q24606852-3066D706-41BA-4D5D-9CD6-2C3DF2AFBA90 Q24613720-28DB72C4-F945-49FD-AE1A-A488FC2991D9 Q26751341-461F4CB2-5FF6-41AE-B466-49FF1C7CFF75 Q26852437-D65415D5-8C6C-4F8C-8080-EECD45BC5A22 Q26998017-80D833A9-9E9A-43F9-8888-3AD9CD3B52EC Q27028048-DDC0B502-AFB3-4292-97A6-7BD4007F8A60 Q28765488-2C440699-6B49-4539-B2B1-19A2082CC7C2 Q30250106-349CC171-CA2F-4DA3-B9D8-ECAFC11B2EF8 Q30472042-F9333E0D-83B9-47F1-B77F-F959F8C631F4 Q31131055-2712DF61-0BA7-4484-BB1B-8D4A7C90F7C6 Q33398485-70EFD999-FA0A-4610-9D0E-F649DC7E7C0B Q33424379-E3CE8523-1B06-4CCE-A9B1-F9BD0F60FAB6 Q33633424-41A41992-D892-49E9-A2FA-F311E7433741 Q33754360-E03F8C00-2A13-4294-9652-5A5318B177DE Q33770680-70D2E6B1-2BF3-4A28-A4C2-768F94E3AEC2 Q33895119-FAF525DF-D085-4930-992F-A848121622B0 Q33985467-99D2AA8C-4288-4E2A-8659-0C57E15FF7BD Q33997879-BCB53CDA-7925-42B5-8837-A8D96CE3ECE1 Q34086952-0D1D293B-DB1E-4E83-ACBA-9633419554C8 Q34088696-BF008C3B-8974-4C77-BC97-D14CC73C11EE Q34206601-7F812284-638E-4E6A-BF6E-1A8F4324D728 Q34245458-084E3998-77E3-4CAD-81E9-6131BAA9C101 Q34554398-26200353-6CEC-4C6B-9EE6-143E2EA096A6 Q34616440-5D13C18B-14C2-4BF1-95A7-B4D6078762EC Q34621802-95CF84C8-47C6-4659-B276-C00EACF7AB37 Q34627163-E1BEDFD5-1CF8-484B-AB91-99ED252A9177 Q34636002-523004C8-76D4-4B9A-A398-82C47D6A5B8A Q34660154-C59EF7E0-FC5F-4DF3-A5DF-7B867B77228E Q34661185-914967B4-27A8-4629-B93C-C621FC002EE4 Q35152107-30397B82-3E47-4918-A1F0-7E1457CA8576 Q35184806-1074A917-78E9-49CB-B724-AABEA7AE8C10 Q35209594-9A7C83AF-BD3F-419F-9DAF-A72A1E4E5CA9 Q35369677-ADA9AD92-DC84-460D-843D-AADFF45C0946 Q35413876-5E931493-6E6A-4240-AC10-584B799185DE Q35562209-AC07E845-4053-49D3-9E2D-B75442D1D422 Q35667342-2C26E35F-694C-4A78-8905-718A3EE936C4 Q35672426-DB0E75BA-7342-4CF4-A074-1FF8436C5FF4 Q35678358-A1C9947A-57B3-4629-922F-7AF50151DE67

P2860

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q43299263

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@en

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@nl

type

label

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@en

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@nl

prefLabel

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@en

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@nl

P1433

Q43299263-22FB1DFE-2B26-4319-A922-1580AF2B1673

P1476

Q43299263-02AED21A-EF16-455B-B677-95874EB25EEB

P2093

Q43299263-04151901-D15E-494A-8341-0C168AA365CD

Q43299263-12C6DC0E-2E7F-4282-91B0-4083D490C16F

Q43299263-1720B0A0-7745-409F-88B0-C46209390301

Q43299263-2C8F2958-6778-4DF9-8972-4B0E857866FE

Q43299263-6D9BB952-BA69-4125-B5E4-E9DA0AC3C3BF

Q43299263-869CD18A-1CE8-4376-AE31-37A71E1D5983

Q43299263-98330953-720F-4B70-BD02-CE4B9FC2FB53

Q43299263-F09CC982-6E83-4145-919E-EF391E809827

Q43299263-FFB1768F-D314-4EC2-9FBF-F1D6206DC0D2

P304

Q43299263-1CCB69E3-2142-4132-B50E-FD69893BDBDB

P31

Q43299263-208A0A3C-D207-49E6-9BE2-46323CAE6FDA

P356

Q43299263-38D92B58-E1A6-42B4-9B7C-23DD63298087

P407

Q43299263-A411E653-B436-4273-8910-ED4DCF049C5B

P433

Q43299263-096A2181-A5B7-4F29-B6A5-A1ACC91F59D0

P478

Q43299263-F63A9826-5384-4882-A9A2-DD02523B071F

P50

Q43299263-95A415A9-6CD9-4369-931F-6B451F9103EC

P577

Q43299263-F04BFC69-5D5C-425E-9733-BEF76EEEA76A

P698

Q43299263-FE0DE08D-AB08-4D99-A864-06C6E99B7DFE

P356

JCO.2008.21.7034

P1433

Journal of Clinical Oncology

P1476

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

@en

P2093

Brad Rosbrook

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Gary Hudes

http://www.w3.org/2001/XMLSchema#string

Jamal Tarazi

http://www.w3.org/2001/XMLSchema#string

Janice P Dutcher

http://www.w3.org/2001/XMLSchema#string

Laura Wood

http://www.w3.org/2001/XMLSchema#string

Peter C Trask

http://www.w3.org/2001/XMLSchema#string

Sinil Kim

http://www.w3.org/2001/XMLSchema#string

Walter M Stadler

http://www.w3.org/2001/XMLSchema#string

P304

4462-4468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.21.7034

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19652060

http://www.w3.org/2001/XMLSchema#string